MS-20 oral solution ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 97 | Ulcerative colitis | 1 |
97. Ulcerative colitis
Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04908644 (ClinicalTrials.gov) | August 18, 2021 | 25/5/2021 | MS-20 on Patients With Ulcerative Colitis(UC) | Study to Evaluate Efficacy and Safety of MS 20 on Patients With Ulcerative Colitis | Ulcerative Colitis | Drug: MS-20 oral solution;Other: Placebo | National Taiwan University Hospital | Microbio Co Ltd | Recruiting | 20 Years | 65 Years | All | 40 | N/A | Taiwan |